The FDA rejects an injectable variant of Johnson & Johnson’s lung cancer drug, Rybrevant.
发布者：BY MARIUS AMBAKK BJORKEDAL，转转请注明出处：https://robotalks.cn/fda-delays-approval-of-jj-lung-cancer-treatment-after-manufacturing-facility-inspection/
FDA delays approval of J&J lung cancer treatment after manufacturing facility inspection
赞 (0)
关于作者
相关推荐
-
EU greenhouse gas emissions saw ‘huge’ drop in 2023
Greenhouse gas emissions in the EU fell by eight percent in 2023—among the biggest drops in decades—new data showed Thursday, though the bloc remains in a race against time to meet…
-
Swave Photonics debuts Holographic eXtended Reality display with tiny-pixel technology
Holographic screen start-up Swave Photonics today revealed the growth of what is declared to be the globe’s initial 3D holographic screen modern technology for small prolonge…
-
Samsung Electronics Canada Partners with Canada Post to Enhance Customer Support Services
TORONTO–( COMPANY CORD)– Samsung Electronic devices Canada is delighted to reveal a brand-new collaboration with Canada Article to boost consumer assistance solutions. …
-
Polestar appoints Jonas Engstr�m Chief Operating Officer
Polestar (Nasdaq: PSNY) has actually assigned Jonas Engstr m to the duty of Principal Operating Policeman (COO). As COO, Jonas’s primary emphasis will certainly be the distri…
-
Vale finds surface cracks in Brazil’s Forquilha III dam
Vale is carrying out better assessments on the Forquilha III dam at Fabrica mine in Ouro Preto, complying with the exploration of surface area splits. The blog post Vale finds surf…
